Skip to content
Review

CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria

Aug 2026 · Archives of Microbiology · Vol 208 · 0 citations · 238 references
Medicine

TL;DR

This study investigates the CRISPR-Cas framework’s potential as a cutting-edge tactic to fight antimicrobial resistance, and finds that the efficiency of CRISPR-Cas is diminished in some bacterial strains due to variations in their CRISPR loci.

View source

Similar papers

Review Open access Jul 2026

CRISPR-ENABLED ANTIMICROBIAL STRATEGIES: REDEFINING PRECISION THERAPY AGAINST MULTIDRUG RESISTANT PATHOGENS

Overall, CRISPR-based antimicrobial therapy represents a transformative approach to precision infectious disease management, with continued technological innovation, interdisciplinary collaboration, and robust clinical validation expected to facilitate its safe, effective, and clinically accessible implementation again...

Dipankar Mukhopadhyay, Dr. Shilanjali Bhalerao, Dr. Vijayendra Gautam et al. · 0 citations
Review Aug 2026

Phage and CRISPR based precision antimicrobials: a dual strategy against multidrug-resistant bacteria

This review critically examines bacteriophage-based antimicrobials, CRISPR-Cas therapeutic systems, and their emerging integration as CRISPR-armed phages, highlighting their comparative advantages, current limitations, and future potential as promising targeted antimicrobial approach platforms requiring further clinica...

Anjaneyulu Musini, V. Yata, Sarad Pawar Naik Bukke et al. · 0 citations
Open access Aug 2026

Establishing Design Principles for CRISPR-Cas Antifungals in Candida albicans

DNA repair is established as a programmable determinant of CRISPR-Cas antifungal activity and provide a mechanistic framework for combinatorial targeting strategies, advancing the development of CRISPR-Cas antifungals.

Christopher J. Cotter, C. Trinh · 0 citations
Review Sep 2026

Emerging CRISPR-Cas, Antibody, and Nanomedicine Strategies Against Antimicrobial Resistance in Critical Care

Four convergent, non-traditional pillars emerged — programmable CRISPR-Cas and CRISPRi genomic tools, monoclonal antibodies and bioconjugates, antimicrobial and anticancer peptides, and stimuli-responsive nanozymes and exosomal carriers — each capable of bypassing classical resistance mechanisms while, at least in prec...

Unknown authors · 0 citations
Review Open access Aug 2026

CRISPR-Cas systems as precision antimicrobials: Reversing the tide of antimicrobial resistance

In vivo models confirm significant reduction of resistant pathogens, supporting clinical translational potential and key challenges remain in off-target effects, manufacturing, and regulatory approval for human use.

Mahsa Khosrojerdi, S. Hashemi, Reza Besharati et al. · 0 citations
Review Open access Aug 2026

Nanotechnology-Driven Strategies to Combat Antimicrobial Resistance in the One Health Era

Recent advances in antimicrobial nanomaterials, nanodrug delivery systems, antibiofilm strategies, and nanodiagnostics are summarized and the potential of nanotechnology to support sustainable AMR management across interconnected human, animal, and environmental sectors is emphasized.

Zakarya Al-Shaebi, Munevver Akdeniz, Omer Aydin · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.